Here are the DEF 14A proxy statements from Candel Therapeutics, Inc. (CADL) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow CADL and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CADL filings page.
Candel Therapeutics is calling a virtual 2026 annual stockholder meeting on June 23, 2026 at 10:00 a.m. Eastern via www.virtualshareholdermeeting.com/CADL2026. Stockholders will elect four Class II directors to serve until 2029 and vote on ratifying KPMG LLP as independent auditor for 2026.
Holders of 73,270,239 shares of common stock as of April 24, 2026 may vote online, by phone, mail or during the webcast. The company uses SEC “Notice and Access” to distribute materials electronically and remains an emerging growth and smaller reporting company, providing scaled governance and executive compensation disclosure.